About the Authors
- Tao Xie
-
* E-mail: tao.xie@pfizer.com (TX); mhidalgo@cnio.es (MH)
Affiliation Oncology Research, Pfizer Worldwide Research and Development, San Diego, California, United States of America
- Monica Musteanu
-
Affiliation CNIO (Spanish National Cancer Research Centre), E-28029, Madrid, Madrid, Spain
- Pedro P. Lopez-Casas
-
Affiliation CNIO (Spanish National Cancer Research Centre), E-28029, Madrid, Madrid, Spain
- David J. Shields
-
Affiliation Oncology Research, Pfizer Worldwide Research and Development, San Diego, California, United States of America
- Peter Olson
-
Affiliation Oncology Research, Pfizer Worldwide Research and Development, San Diego, California, United States of America
- Paul A. Rejto
-
Affiliation Oncology Research, Pfizer Worldwide Research and Development, San Diego, California, United States of America
- Manuel Hidalgo
-
* E-mail: tao.xie@pfizer.com (TX); mhidalgo@cnio.es (MH)
Affiliation CNIO (Spanish National Cancer Research Centre), E-28029, Madrid, Madrid, Spain
Competing Interests
The authors have the following interests: The study was funded by Pfizer Inc. Tao Xie, David J. Shields, Peter Olson and Paul A. Rejto are employees of Pfizer. There are no patents, products in development or marketed products to declare. This did not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials.
Author Contributions
Conceived and designed the experiments: TX DJS PO PAR MH. Performed the experiments: MM PPL. Analyzed the data: TX DJS PO. Contributed reagents/materials/analysis tools: TX MM PPL DJS PO. Wrote the paper: TX MM PPL DJS PO PAR MH.